RAPT Therapeutics Stock Soars As Atopic Dermatitis Candidate Shows Promising Action In Early-Stage Study
RAPT Therapeutics Inc (NASDAQ:RAPT) has announced topline results from its Phase 1b trial of RPT193 as monotherapy for moderate-to-severe atopic dermatitis…